Latest:
Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment
Kerstin Junker, MD, associate professor, Department of Urology, Universit
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kevin Harrington, MD, PhD, The Royal Marsden NHS Foundation
Latest:
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer
Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, MS, is a professor and director of the Division of Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and the Louisa and Rand Glenn Family Chair in Breast Cancer Research and director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University in Atlanta, Georgia.
Latest:
Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO
Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.
Kevin R. Kelly, MD, PhD
Latest:
Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Kevin S. Hughes, MD
Latest:
Dr. Hughes on RT in Elderly Patients With ER+ Breast Cancer
Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.
Kevin W. Su, BS
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Kevin Wright
Latest:
Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLC
January 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.